首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
Authors:Taeang Arai  Masanori Atsukawa  Akihito Tsubota  Tadashi Ikegami  Noritomo Shimada  Keizo Kato  Hiroshi Abe  Tomomi Okubo  Norio Itokawa  Chisa Kondo  Shigeru Mikami  Toru Asano  Yoshimichi Chuganji  Yasushi Matsuzaki  Hidenori Toyoda  Takashi Kumada  Etsuko Iio  Yasuhito Tanaka  Katsuhiko Iwakiri
Affiliation:1. Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan;2. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan;3. Core Research Facilities for Basic Science, The Jikei University School of Medicine, Tokyo, Japan;4. Department of Internal Medicine, Division of Hepatology and Gastroenterology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan;5. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan;6. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Japan;7. Department of Internal Medicine, Division of Gastroenterology, Kikkoman General Hospital, Noda, Japan;8. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan;9. Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan;10. Department of Virology and Liver Unit, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
Abstract:
Keywords:chronic hepatitis C  chronic kidney disease  direct‐acting antiviral  genotype 1  ombitasvir  paritaprevir  ritonavir
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号